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Abstract 
CIC is a tissue-specific transcriptional repressor 
that is highly conserved between metazoan 
organisms and is required for the normal 
development of multiple adult structures. CIC 
functions to transduce receptor tyrosine kinase 
(RTK) signalling into gene expression changes 
through a mechanism termed default repression, 
wherein CIC is bound to target gene promoters or 
enhancers and inhibits transcription in the absence 
of signal.  
This CIC-DNA interaction can be inhibited through 
activation of the RTK core signalling molecule 
mitogen-activated protein kinase (MAPK), which 
then allows for the transcription of CIC targets 
through this RTK-MAPK signalling axis. 
Components of RTK signalling are commonly 
dysregulated in cancers, possibly implying that CIC 
alterations observed in specific cancer types (e.g. 
oligodendroglioma and Ewing-like sarcomas) are a 
form of RTK signalling dysregulation that drives 
oncogenesis. CIC is also specifically expressed in 
cells of the developing central nervous system and 
its dysfunction is associated with the 
neurodegenerative disorder spinocerebellar ataxia 
type 1, implicating CIC in neuronal cell 
development and/or homeostasis. Other possible 
cellular and physiological roles for CIC include cell 
cycle control, ATP-citrate lyase phosphorylation, 
reactive oxygen species homeostasis, and bile acid 
homeostasis. 
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CIC is located on the positive strand and spans 
approximately 27 kilobases. It has 21 exons. 
According to Entrez-Gene, CIC maps to 
NC_000019.10 of the assembly GRCh38.p2. 
Transcription 
There are two known isoforms of CIC: short (CIC-
S) and long (CIC-L).  CIC-S and CIC-L have 
alternative transcription start sites at exon 1 and 
exon 0, respectively, and share exons 2-20 (Figure 
1). 
Pseudogene 
According to Entrez-Gene, CIC has 28 related 
pseudogenes. 
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Figure 1.  Exon structure of 2 main CIC isoforms in humans: CIC short (CIC-S) and long (CIC-L). The highly conserved DNA-
binding high mobility group (HMG) box domain is encoded mostly by exon 5 and partially by exon 6 while the highly conserved 





In Drosophila and zebrafish, CIC mRNA is 
maternally provided to the egg (Jimenez et al. 2000; 
Chen et al. 2014). In zebrafish and mice, CIC 
mRNA is detected at various developmental stages, 
especially in the developing central nervous system 
(Lee et al. 2002; Chen et al. 2014). In adult mice, 
CIC mRNA is relatively highly expressed in the 
brain, spleen, testis, and kidney. CIC mRNA may 
also be expressed in the heart, lung, mammary 
tissue, thymus, and lymph nodes in adult mice (Lee 
et al. 2002). 
Localisation 
CIC-S and CIC-L localize to both the cytoplasm 
and the nucleus in multiple human cell lines. CIC 
may also accumulate close to the mitochondria 
(Chittaranjan et al. 2014). 
Function 
CIC has invariably been observed to act as a 
repressor of transcription through its DNA-binding 
activity. CIC has a high mobility group (HMG) box 
domain that confers binding to an octameric DNA 
motif T(G/C)AATG(A/G)A within the promoters 
or enhancers of its target genes (Jimenez et al. 
2012). In Drosophila, presence of this octameric 
motif at the regulatory region of a reporter gene was 
necessary to confer CIC-mediated transcriptional 
repression, although recruitment of a corepressor 
protein such as Groucho may be necessary to confer 
repression (Ajuria et al. 2011). CIC's DNA-binding 
activity can be inhibited through the activation 
(phosphorylation) of mitogen-activated protein 
kinase (MAPK), a core signaling molecule of 
receptor tyrosine kinase (RTK) pathways (Jimenez 
et al. 2002; Dissanayake et al. 2011). This provides  
a mechanism for allowing CIC target gene 
transcription upon RTK signaling. MAPK 
potentially regulates CIC's transcriptionally 
repressive activity in three ways: through direct 
binding with CIC (Astigarraga et al. 2007, Futran et 
al. 2015), through the activation of the downstream 
signaling molecule p90RSK (Figure 2) to inhibit 
CIC's DNA-binding activity (Dissanayake et al. 
2011), or through influencing CIC's 
nucleocytoplasmic shuttling (Dissanayake et al. 
2011, Grimm et al. 2012). CIC levels in turn also 
positively regulate MAPK phosphorylation in vivo 
in Drosophila by protecting MAPK from 
phosphatases (Kim et al. 2011). 
CIC functions in multiple developmental contexts 
in both Drosophila and mammals. For example, in 
Drosophila, CIC can regulate proper embryonic 
patterning, cell differentiation to form wing vein 
cells, and cell proliferation in the developing eye. In 
all these contexts, CIC functions in cells by 
restricting the expression of specific target genes 
when an extracellular growth signaling molecule is 
absent (Jimenez et al. 2002; Roch et al. 2002; 
Tseng et al. 2007).  
CIC has also been reported to function in reactive 
oxygen species homeostasis (Krivy et al. 2013), 
ATP-citrate lyase phosphorylation (Chittaranjan et 
al. 2014), and bile acid homeostasis (Kim et al. 
2015). 
Homology 
CIC has homologs in mice, zebrafish, Drosophila, 
and C. elegans (Jimenez et al. 2000; Lee et al. 
2002). Amino acid sequence identity of CIC's N1 
domain, HMG box domain, and C1 motif (Figure 2) 
is highly conserved between species (Jimenez et al 
2012). This indicates that at least some of CIC's 
biochemical functions are evolutionary conserved 
between animals. 
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Figure 2.  Functional domains of CIC short (CIC-S) and long (CIC-L) isoforms in humans. N1:  Conserved CIC-L N-terminal 
domain of unknown function. Ataxin-1 BD:  Binding domain that directly interacts with Ataxin-1 (Lam et al. 2006; Kim et al. 
2013). 14-3-3 BD:  binding domain that directly interacts with 14-3-3 proteins. This domain harbours a serine residue that is 
phosphorylated by p90RSK to mediate 14-3-3 binding and consequent inhibition of DNA binding upon MAPK activation. An 
additional 14-3-3 BD flanking the other end of the HMG domain may also be required for 14-3-3 dimer recognition (Dissanayake 
et al. 2011). HMG: DNA-binding high mobility group box domain (Jimenez et al. 2000; Lee et al. 2002). NLS: Nuclear localisation 
signal recognized by the nuclear importer KPNA3. Phosphorylation of two nearby serine residues may mask the NLS and 
potentially interferes with nuclear shuttling upon MAPK activation. Other NLS sequence(s) may be encoded within the HMG 
domain (Dissanayake et al. 2011). C1: Highly conserved c-terminal motif that may be essential for CIC-mediated transcriptional 




CIC-rearranged Ewing-like sarcomas 
The overwhelming majority of Ewing 
sarcoma/primitive neuroectodermal family of 
tumours (EFTs) harbour rearrangements of the 
EWSR1 gene with an ETS family member (Delattre 
et al. 1994; Mariño-Enrèquez & Fletcher 2014). 
However, up to 2/3 of EWSR1 fusion-negative 
EFTs may harbour rearrangements of CIC with a 
copy of DUX4 on either 4q35 or 10q26. CIC-
DUX4. EFTs are aggressive and typically share 
characteristics such as geographical necrosis and  
greater heterogeneity in nuclear shape and size than 
classical EFTs (Italiano et al. 2012). CIC-DUX4 
proteins have oncogenic transforming potential in 
vitro and may drive oncogenesis by strongly 
activating transcription of CIC's oncogenic target 
genes ETV1, ETV4, and ETV5 instead of normally 
repressing them (Kawamura-Saito et al. 2006). 
Consistent with this, EWSR1-ETV1 and EWSR1-
ETV4 fusions, which presumably function as 
aberrant versions of the transcription factors ETV1 
and ETV4, respectively, have been observed in 
EFTs (Jeon et al. 1995; Kaneko et al. 1996).  
EFTs with CIC-FOXO4 fusions have also been 
reported (Sugita et al. 2014; Solomon et al. 2014). 
 
 
Figure 3.  CIC-S: short isoform of CIC. HMG: high-mobility group. C1 motif: highly conserved c-terminal domain. Recurrently 
detected mutations are indicated in stacked symbols. Frequencies of different mutation types are given in parentheses. 
Mutational data were gathered from multiple sources (Bettegowda et al. 2011; Jiao et al. 2012; Sahm et al. 2012; Yip et al. 2012) 
and the cbioportal database (Gao et al. 2013; Chan et al. 2014). The results shown here are in part based upon data generated 
by the TCGA Research Network: http://cancergenome.nih.gov/. 
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Figure 4.  Frequency of CIC alterations detected in non-glioma cancers. Figure was obtained and modified from the cbioportal 
database (Cerami et al. 2012; Gao et al. 2013). The results shown here are in whole or part based upon data generated by the 
TCGA Research Network: http://cancergenome.nih.gov/. Cancer types with 2 or more detected CIC alterations are shown. CNA: 
copy number alteration. 
 
Oligodendroglioma 
CIC mutations are detected in about 70% of 
"classical" oligodendrogliomas (ODGs, i.e. gliomas 
harbouring deletions of the chromosomal arms 1p 
and 19q) (Bettegowda et al. 2011; Yip et al. 2012). 
Classical ODGs also present with a characteristic 
set of other somatic mutations, namely in IDH1 or 
IDH2 (in 100% of cases), in the TERT promoter 
(about 90% of cases), and in FUBP1 (about 25-40% 
of cases) (Bettegowda et al. 2011; Sahm et al. 2012; 
Jiao et al. 2012; Labussire et al. 2014). This 
indicates potential synergistic interactions between 
these mutations to promote ODG progression. 
Different types of detected CIC mutations seem to 
converge on conferring a CIC loss-of-function 
phenotype, indicating CIC mutations may inactivate 
a tumour suppressive activity (Gleize et al. 2015). 
A CIC mutation in a 1p/19q co-deleted background 
may also be compatible with the notion of a tumour 
suppressive role for CIC, since one allele is lost as a 
consequence of 19q loss while the other allele is 
mutated. However, there is an enrichment of CIC 
mutations that affect a single amino acid residue 
and may preserve CIC's structure (Figure 3). Such 
"hotspots" are often detected in oncogenes (Liu et 
al. 2011; Stehr et al. 2011). Multiple distinct CIC 
mutations can arise within different areas of a 
single ODG lesion (Suzuki et al. 2015), possibly 
implicating the importance of CIC mutations in 
driving clonal expansion but not necessarily tumour 
initiation. 
Other cancers 
Recurrent somatic CIC mutations, deletions, and 
amplifications have been detected in a number of 
other cancer types (Figure 4). Loss of CIC 
expression is also implicated in prostate cancer 
progression (Choi et al. 2015). CIC alterations may 
therefore promote oncogenesis in various cancers. 
Spinocerebellar ataxia type 1 
Spinocerebellar ataxia type 1 (SCA1) is an 
inherited neurodegenerative disorder that is caused 
by the production of a toxic form of the Ataxin-1 
protein harbouring an expanded tract of glutamine 
residues (polyQ Ataxin-1) (Orr et al. 1993).  
SCA1 pathogenesis is associated with a direct 
physical interaction of polyQ Ataxin-1 with CIC in 
a large (about 1.8 MDa) complex, as well as with a 
decrease in wild type Ataxin-1-CIC complex 
formation.  
Modulation of CIC's transcriptionally repressive 
activity by polyQ Ataxin-1 provides a possible 
mechanistic basis for SCA1 pathogenesis (Lam et 
al. 2006; Bowman et al. 2007). SCA1 pathogenesis 
may also result from the preferential accumulation 
of another polyQ Ataxin-1 complex that includes 
the RBM17 protein and excludes CIC (Lim et al. 
2008). In a mouse model of SCA1, a modest 
exercise regimen extends longevity by reducing 
CIC levels in the brainstem. CIC loss through 
genetic perturbation also mitigates multiple SCA1 
phenotypes in this model (Fryer et al. 2011). 
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